The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
p53 protein, interferon-γ, and NF-κB levels are elevated in the parkinsonian brain
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The p53, interferon-gamma, and NF-κB protein levels in the caudate nucleus are significantly higher in PD patients than in controls, whereas p53 levels are not altered in the substantia nigra, putamen, or cerebral cortex.235”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [235]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mogi, M., Harada, M., Riederer, P., Narabayashi, H., Fujita, K., & Nagatsu, T. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90746-3 · Cited by 986
Self-citationImamura, K., Hishikawa, N., Sawada, M., Nagatsu, T., Yoshida, M., & Hashizume, Y. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0766-2 · Cited by 791
Self-citationRole of cytokines in inflammatory process in Parkinson’s disease
Sawada, M., Imamura, K., & Nagatsu, T. (2006) · Parkinson’s Disease and Related Disorders · doi:10.1007/978-3-211-45295-0_57 · Cited by 331
Self-citation
Cited by
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
Peripheral cytokines profile in parkinson’s disease
Reale, M., Iarlori, C., Thomas, A., Gambi, D., Perfetti, B., Di Nicola, M., & Onofrj, M. (2009) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2008.07.003 · Cited by 547
Molecular Mechanisms and Clinical Implications of Reversible Protein S -Glutathionylation
Mieyal, J. J., Gallogly, M. M., Qanungo, S., Sabens, E. A., & Shelton, M. D. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2089 · Cited by 523
Miñones-Moyano, E., Porta, S., Escaramís, G., Rabionet, R., Iraola, S., Kagerbauer, B., Espinosa-Parrilla, Y., Ferrer, I., Estivill, X., & Martí, E. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr210 · Cited by 482
Neuronal Cell Death Mechanisms in Major Neurodegenerative Diseases
Chi, H., Chang, H.-Y., & Sang, T.-K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103082 · Cited by 412
Koprich, J. B., Reske-Nielsen, C., Mithal, P., & Isacson, O. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-8 · Cited by 355
MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration
Cebrián, C., Zucca, F. A., Mauri, P., Steinbeck, J. A., Studer, L., Scherzer, C. R., Kanter, E., Budhu, S., Mandelbaum, J., Vonsattel, J. P., et al. (2014) · Nature Communications · doi:10.1038/ncomms4633 · Cited by 338
Czarny, P., Wigner, P., Galecki, P., & Sliwinski, T. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.06.036 · Cited by 310
The pharmacological regulation of cellular mitophagy
Georgakopoulos, N. D., Wells, G., & Campanella, M. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2287 · Cited by 319
Dopamine, Immunity, and Disease
Channer, B., Matt, S. M., Nickoloff-Bybel, E. A., Pappa, V., Agarwal, Y., Wickman, J., & Gaskill, P. J. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000618 · Cited by 308
Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease
Collins, L. M., Toulouse, A., Connor, T. J., & Nolan, Y. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.028 · Cited by 306
Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinson’s disease
Taylor, J. M., Main, B. S., & Crack, P. J. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2012.12.016 · Cited by 303
Cell death pathways in Parkinson’s disease: proximal triggers, distal effectors, and final steps
Levy, O. A., Malagelada, C., & Greene, L. A. (2009) · Apoptosis · doi:10.1007/s10495-008-0309-3 · Cited by 287
Microglial phenotypes in Parkinson’s disease and animal models of the disease
Joers, V., Tansey, M. G., Mulas, G., & Carta, A. R. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.006 · Cited by 285
Alqahtani, T., Deore, S. L., Kide, A. A., Shende, B. A., Sharma, R., Dadarao Chakole, R., Nemade, L. S., Kishor Kale, N., Borah, S., Shrikant Deokar, S., et al. (2023) · Mitochondrion · doi:10.1016/j.mito.2023.05.007 · Cited by 274
Shaping the Nrf2-ARE-related pathways in Alzheimer’s and Parkinson’s diseases
Fão, L., Mota, S. I., & Rego, A. C. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100942 · Cited by 270
Statins: Multiple neuroprotective mechanisms in neurodegenerative diseases
Wang, Q., Yan, J., Chen, X., Li, J., Yang, Y., Weng, J., Deng, C., & Yenari, M. A. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2010.04.006 · Cited by 130
Neuroprotective effects of short-chain fatty acids in MPTP induced mice model of Parkinson's disease
Hou, Y., Li, X., Liu, C., Zhang, M., Zhang, X., Ge, S., & Zhao, L. (2021) · Experimental Gerontology · doi:10.1016/j.exger.2021.111376 · Cited by 101
The role of the immune system in neurodegenerative disorders: Adaptive or maladaptive?
Doty, K. R., Guillot-Sestier, M.-V., & Town, T. (2015) · Brain Research · doi:10.1016/j.brainres.2014.09.008 · Cited by 104
Bantle, C. M., Phillips, A. T., Smeyne, R. J., Rocha, S. M., Olson, K. E., & Tjalkens, R. B. (2019) · npj Parkinson's Disease · doi:10.1038/s41531-019-0090-8 · Cited by 89
Peripheral Chemo-Cytokine Profiles in Alzheimers and Parkinsons Diseases
Reale, M., Greig, N., & Kamal, M. (2009) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955709789055199 · Cited by 82
Hwang, I. K., Lee, C. H., Li, H., Yoo, K.-Y., Choi, J. H., Kim, D. W., Kim, D.-W., Suh, H.-W., & Won, M.-H. (2008) · Neurochemical Research · doi:10.1007/s11064-007-9584-6 · Cited by 40
The Role of LRRK2 in the Regulation of Monocyte Adhesion to Endothelial Cells
Hongge, L., Kexin, G., Xiaojie, M., Nian, X., & Jinsha, H. (2015) · Journal of Molecular Neuroscience · doi:10.1007/s12031-014-0312-9 · Cited by 36
Parkinson’s Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?
Gundersen, V. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.580311 · Cited by 33
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Rideout, H. J., & Re, D. B. (2017) · Advances in Neurobiology · doi:10.1007/978-3-319-49969-7_10 · Cited by 17
Leptin levels in patients with Parkinson's disease: A systematic review and meta-analysis
Rahnemayan, S., Mirghafourvand, M., Fathalizadeh, A., Faramarzi, E., Reyhanifard, A., Mahmoodpoor, A., & Sanaie, S. (2021) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2020.11.001 · Cited by 14
Metadata
- Authors
- Mogi, M., Kondo, T., Mizuno, Y., & Nagatsu, T.
- Venue
- Neuroscience Letters
- Publisher
- Elsevier BV
- Published
- 2007-02
- Volume
- 414
- Issue
- 1
- Pages
- 94-97
- ISSN
- 0304-3940 (ISSN-L)
- OpenAlex
- W1973114962
- Cited by
- 242
- References
- 3
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.